GRK2 in Lymphocytes
Expanding the Arsenal of Heart Failure Prognostics
Joshua G. Travers, Allison E. Schafer, Burns C. Blaxall

Heart failure (HF) has been described as the inability of the myocardium to deliver oxygen and nutrients to a degree commensurate with the metabolic requirements of the body. Myocardial dysfunction induces compensatory neurohumoral mechanisms, including the sympathetic nervous system (SNS), as an attempt to preserve contractile performance. Mediators of the SNS consist predominantly of 2 catecholamines, namely epinephrine and norepinephrine (NE), released by cardiac sympathetic nerve terminals or secreted directly into the circulation by the adrenal medulla. Effects of these neurotransmitters are mediated through cell surface adrenergic receptors (ARs), members of the G protein–coupled receptor superfamily. Stimulation of the β-AR promotes a conformational change to activate the heterotrimeric G protein Gα and Gβγ subunits, promoting positive inotropic and chronotropic effects culminating in improved myocardial function.1

This functionally beneficial pathway refers exclusively, however, to acute receptor activation; sustained β-AR stimulation, as occurs in most cardiovascular disease, is characterized by molecular modifications, leading to reduced receptor sensitivity and membrane expression. Receptor desensitization and downregulation are regulatory processes thought to moderate persistent agonist stimulation to prevent catecholamine-induced toxicity. The desensitization process is initiated in large part by agonist-dependent phosphorylation of the receptor’s cytoplasmic tail by G protein–coupled receptor kinase 2 (GRK2), a serine/threonine kinase. GRK2 is a cytosolic enzyme that localizes to the plasma membrane after recruitment by active Gβγ subunits. This is followed by recruitment of β-arrestin to the phosphorylated receptor, which prevents recoupling of the dissociated cognate G protein and targets the receptor for internalization and eventual degradation. It is now appreciated that chronic SNS activity and subsequent GRK2-mediated receptor downregulation result in a loss of responsiveness to catecholamines and contribute to further contractile dysfunction and increased patient mortality.2,3

Pivotal studies have indicated that properties of β-AR signaling seem to be recapitulated in circulating white blood cells. In 1986, Brodde et al reported that, in human subjects, the density of β-ARs on circulating lymphocytes directly correlated with the density and functional responsiveness of β-ARs in solid tissue, specifically right atrial appendages.4 Subsequent data demonstrated that, in addition to β-ARs, there was a direct association between lymphocyte and cardiac GRK2 expression and activity in human HF patients.5 Thus, measurement of lymphocytic GRK2 appeared to provide an accurate assessment of the relative levels of GRK2, as well as β-AR signaling, in the myocardium. This phenomenon has been further examined in end-stage HF patients who have been placed on mechanical circulatory support. Left ventricular assist devices have become a key therapeutic strategy in the management of end-stage HF, and left ventricular assist device–induced unloading has been associated with partial normalization of myocardial structure and function, along with partial restoration of β-AR signaling and GRK2 downregulation in cardiomyocytes.6,7 Interestingly, this restoration in β-AR signaling and GRK2 expression after left ventricular assist device implantation is mirrored by the diminished expression of GRK2 in lymphocytes.7 Taken together, this corroborates the potential for using lymphocytes to monitor disease-induced β-AR signaling changes in the heart.

In the present study by Rengo et al,8 the authors have evaluated the prognostic potential of lymphocyte GRK2 levels in predicting outcomes in patients with HF. Lymphocyte GRK2 levels were detected in immunoprecipitated lymphocyte extracts by Western blotting. Selection of participants for the study was based on the diagnosis of HF of either ischemic or nonischemic pathogenesis. The study group consisted of 257 patients, and those enrolled fell within either Class II or III of the New York Heart Association functional classification system. Echocardiographic analysis, perhaps the most useful noninvasive tool for diagnosis, revealed that patients exhibited typical characteristics of hemodynamic dysfunction, including reduced mean left ventricular ejection fraction. Measurement of the blood concentration of B-type natriuretic peptide was used as a complementary diagnostic approach because elevation in the secretion of this family of hormones is known to occur after cardiac injury. Serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) are commonly measured to assess heart disease severity, and as anticipated, the patients demonstrated significantly elevated serum NT-proBNP levels. Plasma NE levels were also measured, and although this represents a somewhat rudimentary assessment that depends considerably on the rate of NE reuptake and clearance from the
circulation, it provides a useful tool for the estimation of SNS activity. These parameters were incorporated into the study to validate the prognostic efficacy of lymphocyte GRK2 level assessment. Patients were followed for an average of 37.5 months; cardiovascular and all-cause deaths were recorded.

The authors first sought to evaluate markers that correlated with patient mortality. New York Heart Association class, left ventricular ejection fraction, serum NT-proBNP, and plasma NE were among the factors significantly associated with cardiovascular mortality in these patients. As observed previously, mean lymphocyte GRK2 protein levels were significantly elevated in HF patients compared with healthy controls. Similar to the established markers of heart disease, elevated lymphocyte GRK2 levels were also significantly associated with patient mortality; analysis revealed a significant difference in lymphocyte GRK2 levels between survivors and nonsurvivors with an average of 1.17±0.62 and 1.66±0.71 DU, respectively. Furthermore, lymphocyte GRK2 expression significantly correlated with age and left ventricular ejection fraction, along with serum NE and NT-proBNP levels. Stratification of age, left ventricular ejection fraction, lymphocyte GRK2, and NT-proBNP data generally depicted a significant, consistent increase along the quartiles of these factors. Finally, NT-proBNP and lymphocyte GRK2 levels appeared to have the greatest impact on cardiovascular-related and all-cause death.

The prognostic values of NT-proBNP and lymphocyte GRK2 were further evaluated by decision curve analysis to investigate the individual and combined clinical net benefit profiles of these markers. Although typical prediction models provide the probability of an event on the basis of a set of prognostic factors, they do not incorporate clinical consequences and do not inform clinical practice. The authors have used a model that is suitable for evaluating alternative clinical prognostic strategies and has advantages over other commonly used measures and techniques. Interestingly, the 2 partial models, evaluating either NT-proBNP or lymphocyte GRK2 independently, show similar net benefit profiles, suggesting the prognostic power of lymphocyte GRK2 level to be equally effective as NT-proBNP. Furthermore, the full model combining these markers demonstrates a clinical net benefit over the utilization of each marker independently. These data present convincing evidence that assessment of lymphocyte GRK2 levels may provide a valuable addition to currently available diagnostic tests for patients with HF.

Inhibitors of the adrenergic and angiotensin signaling pathways have become the standard of care for heart disease patients among all degrees of severity. Interestingly, the use of β-blockers did not significantly correlate with lymphocyte levels of GRK2, nor did it effectively predict mortality in these patients. Although more effective markers may have overshadowed the prognostic value of the use of these medications, it is possible that these data also identify inefficient protection against cardiovascular-related mortality. This potential absence in protection suggests the need for the development of novel therapies for the treatment of HF. As a chief component in the β-AR downregulation process, GRK2 represents an attractive target for the amelioration of aberrant SNS activity in the setting of HF. Preclinical studies from these authors and others have demonstrated that GRK2 inhibition by either peptides or small molecules can improve cardiac function and reverse pathological remodeling in animal models of HF.

The manuscript by Rengo et al is the first to show the prognostic capacity of lymphocyte GRK2 levels to independently predict mortality in HF patients. Moreover, it has demonstrated strong prognostic efficacy equivalent to, and synergistic with, the evaluation of NT-proBNP levels. These findings provide further evidence advocating for the measurement of lymphocyte GRK2 to indirectly evaluate adrenergic activity in the myocardium and approximate heart disease severity (Figure). Future studies will help to further determine its efficacy in the evaluation and guidance of treatment strategies in these patient populations. As the authors have suggested, assessment of a larger population, inclusive of patients in additional disease classes, will ultimately be necessary to confirm the findings presented in their study. Furthermore, with proof of concept established, development of a high-throughput assay to assess lymphocyte GRK2 expression will be necessary before translation into the clinic. These results
present strong evidence that lymphocyte GRK2 levels provide independent and synergistic prognosis with existing HF biomarkers, and future studies will further establish its clinical prognostic efficacy.

**Sources of Funding**

This work was supported by National Institutes of Health grants R01 HL129772, R01 HL132551, and P01 HL069779 (B.C. Blaxall) and a Predoctoral Fellowship from the Pharmaceutical Research and Manufacturers of America Foundation (J.G. Travers).

**Disclosures**

None.

**References**

9. McMurray JJ, Adamopoulos S, Anker SD, et al; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869. doi: 10.1093/eurjhf/hfs105.

**Key Words:** Editorial  ■  adrenergic receptors  ■  epinephrine  ■  GRK2  ■  heart failure  ■  prognosis
GRK2 in Lymphocytes: Expanding the Arsenal of Heart Failure Prognostics
Joshua G. Travers, Allison E. Schafer and Burns C. Blaxall

Circ Res. 2016;118:1049-1051
doi: 10.1161/CIRCRESAHA.116.308542
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/118/7/1049

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/